Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM1812 in Normal to Overweight or Obese Subjects
NCT07224399Phase 1Active, not recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BGM1812 in obesity (4 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Number of treatment adverse events at 9 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
BGM1812
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07224399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224399.